Skip to main content
MR

Mannin Research

Mannin Research is developing a first-in-class therapeutic eye drop that targets the reduction of intraocular pressure in patients with Primary Open-Angle Glaucoma by restoring normal fluid flow in the eye. Utilizing a proprietary research platform, the company aims to create a pipeline of novel therapeutics for various vascular diseases, including Cystic Kidney Disease and Pediatric Glaucoma.

Founded 20166700+ followers
Updated 20 months ago

Funding

$3.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

QB
Funding rounds are not available yet.

Founders

Product

Problem

Primary open-angle glaucoma (POAG) is characterized by elevated intraocular pressure (IOP), which damages the optic nerve and leads to progressive vision loss. Current treatments often have limited efficacy or significant side effects, highlighting the need for novel therapeutic approaches. Existing treatments do not target the underlying mechanism of fluid flow regulation in the eye.

Solution

Mannin Research is developing a first-in-class therapeutic eye drop designed to reduce intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG). The investigational drug aims to restore normal fluid flow within the eye, addressing a key underlying cause of elevated IOP. By targeting this mechanism, the eye drop offers a potentially more effective and targeted approach to managing glaucoma compared to existing treatments. The company's proprietary research platform supports the development of a pipeline of novel therapeutics for various vascular diseases.

Target Audience

The primary target audience includes patients diagnosed with primary open-angle glaucoma (POAG) who require effective and convenient IOP-lowering treatments.

Features

  • First-in-class therapeutic eye drop formulation
  • Targets the restoration of normal fluid flow in the eye
  • Designed for easy self-administration
  • Addresses a key underlying cause of elevated IOP in POAG
  • Proprietary research platform for vascular disease therapeutics
This profile is AI-generated and may contain inaccuracies.